The tweet was deleted by the author.
But we saved everything 🙂.
One in three patients with large B-cell lymphoma (LBCL) experience cancer recurrence after receiving first-line treatment, according to Allogene Therapeutics.
The company is advancing its ALPHA3 clinical trial, which combines investigational minimal residual disease (MRD) testing technology and an off-the-shelf CAR-T product, aiming to enable earlier intervention and potentially improve cure rates for patients. The ALPHA3 study seeks to address a critical unmet need by using MRD diagnostics to identify relapses sooner in the treatment process.
View post on X Loading...
Allogene is pursuing wider access to off-the-shelf CAR T cell therapy for LBCL patients with early ALPHA3 trial results, according to a previous report. The company aims to expand the reach of CAR T technology through its investigational AlloCAR T platform, as detailed in an earlier announcement. Both initiatives focus on developing alternatives to autologous CAR T treatments.